Monural (Fosfomycin Trometamol)

• Monural (fosfomycin trometamol) belongs to the phosphonic acid antibiotic class and is employed in the management of infections affecting the urinary tract.
• Uncomplicated urinary tract infection: provides a single oral dose that eradicates common uropathogens, relieving symptoms such as dysuria, frequency, and urgency.
• Acute uncomplicated cystitis: single‑dose therapy that clears infection caused by susceptible Escherichia coli and other typical bacteria.
• Uncomplicated urinary tract infection (female): single‑dose treatment that alleviates typical symptoms in adult women.

• Fosfomycin trometamol inhibits the bacterial enzyme MurA (phosphoenolpyruvate transferase), which catalyzes the first step of peptidoglycan synthesis in the cell wall. By blocking this enzymatic reaction, the drug prevents formation of a functional cell wall, leading to bacterial lysis and eradication of susceptible organisms.

Adverse reactions to Monural may range from mild, transient events to rare but serious conditions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools that are usually self‑limiting.
• Abdominal pain: cramping or discomfort in the stomach area.
• Headache: mild tension‑type headache.
• Dizziness: transient feeling of light‑headedness.
• Vomiting: occasional emesis after dosing.

Serious or Rare Side Effects

• Allergic reactions: rash, pruritus, or anaphylaxis in hypersensitive individuals.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Severe skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic enzyme elevation: abnormal liver function tests requiring monitoring.
• Hematologic abnormalities: rare cases of neutropenia or thrombocytopenia.

• When prescribing Monural, clinicians should consider several precautionary measures to ensure safe use.
• Assess renal function: adjust use in patients with severe renal impairment.
• Avoid in known hypersensitivity: do not prescribe to individuals allergic to fosfomycin or excipients.
• Use with caution in pregnancy: safety not established; weigh benefits against potential risks.
• Monitor gastrointestinal events: advise patients to report persistent diarrhea or abdominal pain.
• Review concomitant medications: consider potential drug‑drug interactions before initiating therapy.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Fosfomycin trometamol can affect, or be affected by, other medicines. Interactions are grouped by clinical significance.

Major Interactions (Avoid)

• Metoclopramide: reduces fosfomycin absorption, diminishing efficacy.
• Cimetidine: may lower systemic exposure to fosfomycin.
• Antacids containing magnesium or aluminum: significantly decrease oral bioavailability.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR; monitor coagulation parameters.
• Oral contraceptives: possible reduction in contraceptive effectiveness; advise additional protection.
• Other antibiotics with overlapping resistance mechanisms: assess for additive resistance risk.
• Diuretics: monitor electrolyte balance if concurrent renal stress is anticipated.